Hostname: page-component-6bb9c88b65-9rk55 Total loading time: 0 Render date: 2025-07-25T19:49:41.419Z Has data issue: false hasContentIssue false
  • English
  • Français

Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder

Published online by Cambridge University Press:  21 November 2018

Marco Solmi Open the ORCID record for Marco Solmi [Opens in a new window] ,
Michele Fornaro ,
Kuniyoshi Toyoshima ,
Andrè F. Carvalho ,
Cristiano A. Köhler ,
Nicola Veronese Open the ORCID record for Nicola Veronese [Opens in a new window] ,
Brendon Stubbs ,
Andrea de Bartolomeis  and
Christoph U. Correll Open the ORCID record for Christoph U. Correll [Opens in a new window]
Marco Solmi*
Affiliation:
Department of Neurosciences, University of Padua, Padua, Italy Neuroscience Center, University of Padua, Padua, Italy
Michele Fornaro
Affiliation:
Section of Psychiatry–Unit on Treatment Resistant Psychosis, and Laboratory of Molecular and Translational Psychiatry, Department of Neuroscience, University School of Medicine Federico II, Naples, Italy New York State Psychiatric Institute (NYSPI), Columbia University, New York, New York
Kuniyoshi Toyoshima
Affiliation:
Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Andrè F. Carvalho
Affiliation:
Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil
Cristiano A. Köhler
Affiliation:
Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil
Nicola Veronese
Affiliation:
National Research Council, Aging Section, Padua, Italy
Brendon Stubbs
Affiliation:
Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, United Kingdom Physiotherapy Department, South London and Maudsley NHS Foundation Trust, London, United Kingdom
Andrea de Bartolomeis
Affiliation:
Section of Psychiatry–Unit on Treatment Resistant Psychosis, and Laboratory of Molecular and Translational Psychiatry, Department of Neuroscience, University School of Medicine Federico II, Naples, Italy
Christoph U. Correll
Affiliation:
Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York Hofstra Northwell School of Medicine, Hempstead, New York Feinstein Institute for Medical Research, Manhasset, New York
*
*Address for correspondence: Marco Solmi, Department of Neurosciences, University of Padua, via Giustiniani, 2, 35128 Padua, Italy. (Email: marco.solmi83@gmail.com)
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

Our aim was to summarize the efficacy and safety of atomoxetine, amphetamines, and methylphenidate in schizophrenia.

Methods

We undertook a systematic review, searching PubMed/Scopus/Clinicaltrials.gov for double-blind, randomized, placebo-controlled studies of psychostimulants or atomoxetine in schizophrenia published up to 1 January 2017. A meta-analysis of outcomes reported in two or more studies is presented.

Results

We included 22 studies investigating therapeutic effects of stimulants (k=14) or measuring symptomatic worsening/relapse prediction after stimulant challenge (k=6). Six studies of these two groups plus one additional study investigated biological effects of psychostimulants or atomoxetine. No effect resulted from interventional studies on weight loss (k=1), smoking cessation (k=1), and positive symptoms (k=12), and no improvement was reported with atomoxetine (k=3) for negative symptoms, with equivocal findings for negative (k=6) and mood symptoms (k=2) with amphetamines. Attention, processing speed, working memory, problem solving, and executive functions, among others, showed from no to some improvement with atomoxetine (k=3) or amphetamines (k=6). Meta-analysis did not confirm any effect of stimulants in any symptom domain, including negative symptoms, apart from atomoxetine improving problem solving (k=2, standardized mean difference (SMD)=0.73, 95% CI=0.10–1.36, p=0.02, I2=0%), and trending toward significant improvement in executive functions with amphetamines (k=2, SMD=0.80, 95% CI=−1.68 to +0.08, p=0.08, I2=66%). In challenge studies, amphetamines (k=1) did not worsen symptoms, and methylphenidate (k=5) consistently worsened or predicted relapse. Biological effects of atomoxetine (k=1) and amphetamines (k=1) were cortical activation, without change in β-endorphin (k=1), improved response to antipsychotics after amphetamine challenge (k=2), and an increase of growth hormone–mediated psychosis with methylphenidate (k=2). No major side effects were reported (k=6).

Conclusions

No efficacy for stimulants or atomoxetine on negative symptoms is proven. Atomoxetine or amphetamines may improve cognitive symptoms, while methylphenidate should be avoided in patients with schizophrenia. Insufficient evidence is available to draw firm conclusions.

Keywords

amphetamineatomoxetineefficacymeta-analysismethylphenidaterelapse predictorsafetyschizophreniastimulantssystematic review

Information

Type
Review
Information
CNS Spectrums , Volume 24 , Issue 5 , October 2019 , pp. 479 - 495
Copyright
© Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

†

MS and MF contributed equally to the article. All authors contributed equally to all stages of the article preparation.

No funding was directly involved in this paper’s preparation.

References

Miyamoto, S, Miyake, N, Jarskog, L, et al. 2012. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012; 17(12): 1206–1227.CrossRefGoogle ScholarPubMed
Kahn, RS, Sommer, IE, Murray, RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015; 1: 15067.CrossRefGoogle ScholarPubMed
Breier, A, Buchanan, RW, Kirkpatrick, B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 1994; 151(1): 20–26.Google ScholarPubMed
Carbon, M, Correll, CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014; 16(4): 505–524.Google Scholar
Buckley, P, Miller, A, Olsen, J, et al. 2001. When symptoms persist: clozapine augmentation strategies. Schizophr Bull. 27(4): 615–628.CrossRefGoogle ScholarPubMed
Carbon, M, Correll, CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014; 19(Suppl 1): 38–52; quiz 35-7, 53.CrossRefGoogle Scholar
Meltzer, HY Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin. 1997; 14(1): 1–20.CrossRefGoogle ScholarPubMed
Samara, MT, Dold, M, Gianatsi, M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016; 73(3): 199–210.CrossRefGoogle ScholarPubMed
Siskind, D, McCartney, L, Goldschlager, R, Kisely, S Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016; 209(5): 385–392.CrossRefGoogle ScholarPubMed
Kane, JM, Correll, CU The role of clozapine in treatment-resistant schizophrenia. JAMA Psychiatry. 2016; 73(3): 187–188.CrossRefGoogle ScholarPubMed
Correll, CU, Rubio, JM, Inczedy-Farkas, G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry. 2017; 74(7): 675–684.CrossRefGoogle ScholarPubMed
Lindenmayer, J-P, Nasrallah, H, Pucci, M, et al. A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities. Schizophr Res. 2013; 147(2–3): 241–252.CrossRefGoogle ScholarPubMed
Sommer, IE, Begemann, MJ, Temmerman, A, Leucht, S Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull. 2012; 38(5): 1003–1011.CrossRefGoogle ScholarPubMed
Fornaro, M, Solmi, M, Perna, G, et al. Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials. Neuropsychiatr Dis Treat. 2016; 12: 1827–1836.CrossRefGoogle ScholarPubMed
Lasser, RA, Dirks, B, Nasrallah, H, et al. Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases. Neuropsychopharmacology. 2013; 38(11); 2140–2149.CrossRefGoogle ScholarPubMed
Curran, C, Byrappa, N, McBride, A Stimulant psychosis: systematic review. Br J Psychiatry. 2004; 185: 196–204.CrossRefGoogle ScholarPubMed
Strakowski, SM, Sax, KW, Setters, MJ, et al. Lack of enhanced response to repeated d-amphetamine challenge in first-episode psychosis: implications for a sensitization model of psychosis in humans. Biol Psychiatry. 1997; 42(9): 749–755.CrossRefGoogle ScholarPubMed
O’Daly, OG, Joyce, D, Stephan, KE, et al. Functional magnetic resonance imaging investigation of the amphetamine sensitization model of schizophrenia in healthy male volunteers. Arch Gen Psychiatry. 2011; 68(6): 545–554.CrossRefGoogle ScholarPubMed
Lieberman, JA, Kane, JM, Sarantakos, S, et al. Prediction of relapse in schizophrenia. Arch Gen Psychiatry. 1987; 44: 597–603.CrossRefGoogle Scholar
Fallon, P, Dursun, S, Deakin, B Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients. Ther Adv Psychopharmacol. 2012; 2(1): 13–22.CrossRefGoogle ScholarPubMed
Demellweek, C, Goudie, A Behavioural tolerance to amphetamine and other psychostimulants: the case for considering behavioural mechanisms. Psychopharmacology (Berl). 1983; 80(4): 287–307.CrossRefGoogle ScholarPubMed
Leduc, P, Mittleman, G Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. Psychopharmacology. 1995; 121: 407–427.CrossRefGoogle ScholarPubMed
Koda, K, Ago, Y, Cong, Y, et al. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem. 2010; 114(1): 259–270.Google Scholar
Moher, D, Liberati, A, Tetzlaff, J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8: 336–341.CrossRefGoogle ScholarPubMed
Higgins, JP, Altman, DG, Gotzsche, PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928.CrossRefGoogle ScholarPubMed
Swerdlow, NR, Tarasenko, M, Bhakta, SG, et al. Amphetamine enhances gains in auditory discrimination training in adult schizophrenia patients. Schizophr Bull. 2016; 43(4): 872–880.Google Scholar
Goldberg, TE, Bigelow, LB, Weinberger, DR, et al. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry. 1991; 148(1): 78–84.Google Scholar
Pietrzak, RH, Snyder, PJ, Maruff, P Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia. Hum Psychopharmacol. 2010; 25(4): 353–358.CrossRefGoogle ScholarPubMed
Daniel, DG, Weinberger, DR, Jones, DW, et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci. 1991; 11(7): 1907–1917.CrossRefGoogle Scholar
Sanfilipo, M, Wolkin, A, Angrist, B, et al. Amphetamine and negative symptoms of schizophrenia. Psychopharmacology (Berl). 1996; 123: 211–214.CrossRefGoogle ScholarPubMed
Friedman, JI, Carpenter, D, Lu, J, et al. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol. 2008; 28(1): 59–63.CrossRefGoogle Scholar
Sacco, KA, Creeden, C, Reutenauer, EL, et al. Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia. Schizophr Res. 2009; 107(2–3): 332–333.CrossRefGoogle Scholar
Martin, P, Dirks, B, Gertsik, L, et al. Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses. J Clin Psychopharmacol. 2014; 34(6): 682–689.CrossRefGoogle ScholarPubMed
Kelly, DL, Buchanan, RW, Boggs, DL, et al. A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry. 2009; 70(4): 518–525.CrossRefGoogle ScholarPubMed
Van Kammen, DP, Bunney, WE Jr, Docherty, JP, et al. d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. Am J Psychiatry. 1982; 139(8): 991–997.Google Scholar
Carpenter, MD, Winsberg, BG, Camus, LA Methylphenidate augmentation therapy in schizophrenia. J Clin Psychopharmacol. 1992; 12(4): 273–275.CrossRefGoogle Scholar
Lieberman, JA, Kane, JM, Gadaleta, D, et al. 1984. Methylphenidate challenge as a predictor of relapse in schizophrenia. Am J Psychiatry. 141(5): 633–638.Google Scholar
Ball, MP, Warren, KR, Feldman, S, et al. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses. 2011; 5(1): 17–25.CrossRefGoogle ScholarPubMed
Van Kammen, DP, Boronow, JJ Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int Clin Psychopharmacol. 1988; 3(2): 111–121.CrossRefGoogle Scholar
Robinson, D, Mayerhoff, D, Alvir, J, et al. Mood responses of remitted schizophrenics to methylphenidate infusion. Psychopharmacology (Berl). 1991; 105(2): 247–252.CrossRefGoogle ScholarPubMed
Sharma, RP, Javaid, JI, Pandey, GN, et al. Pharmacological effects of methylphenidate on plasma homovanillic acid and growth hormone. Psychiatry Res. 1990; 32(1): 9–17.CrossRefGoogle ScholarPubMed
Pandurangi, AK, Goldberg, SC, Brink, DD, et al. Amphetamine challenge test, response to treatment, and lateral ventricle size in schizophrenia. Biol Psychiatry.1989; 25(2): 207–214.CrossRefGoogle Scholar
Schulz, SC, Van Kammen, DP, Pickar, D, et al. Response of plasma beta-endorphin immunoreactivity to d-amphetamine and placebo in schizophrenic patients. Psychiatry Res. 1982; 7(2): 171–178.CrossRefGoogle ScholarPubMed
Sharma, RP, Javaid, JI, Pandey, GN, et al. Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients. Biol Psychiatry. 1991; 30(5): 459–466.CrossRefGoogle ScholarPubMed
Lieberman, JA, Alvir, J, Geisler, S, et al. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology. 1994; 11(2): 107–118.CrossRefGoogle Scholar
Barch, DM, Carter, CS Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res. 2005; 77(1): 43–58.CrossRefGoogle ScholarPubMed
Man, KK, Coghill, D, Chan, EW, et al. Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system. Transl Psychiatry. 2016; 6(11): e956.CrossRefGoogle Scholar
Ashok, AH, Mizuno, Y, Volkow, ND, Howes, OD Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. JAMA Psychiatry. 2017; 74(5): 511–519.CrossRefGoogle ScholarPubMed
Millan, MJ, Agid, Y, Brune, M, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 2012; 11(2): 141–168.CrossRefGoogle ScholarPubMed
Howes, OD, Kambeitz, J, Kim, E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012; 69(8): 776–786.CrossRefGoogle Scholar
Kambeitz, J, Abi-Dargham, A, Kapur, S, Howes, OD Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. Br J Psychiatry. 2014; 204(6): 420–429.CrossRefGoogle ScholarPubMed
Demjaha, A, Murray, RM, McGuire, PK, et al. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012; 169(11): 1203–1210.CrossRefGoogle ScholarPubMed
Demjaha, A, Egerton, A, Murray, RM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014; 75(5): e11–3.CrossRefGoogle ScholarPubMed